Navigation Links
Delisting Notification Received from the American Stock Exchange
Date:5/30/2008

Company to evaluate appeal options

TORONTO, May 30 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced it has been notified by the American Stock Exchange (the "AMEX") that it will not continue to support PreMD's plan for regaining compliance with the continued listing standards and that it intends to delist the Company's common stock from the Exchange by filing a delisting application with the Securities and Exchange Commission (the "SEC") pursuant to Section 1009(d) of the AMEX Company Guide (the "Company Guide"). The determination by the staff of the AMEX to initiate the delisting of the common stock from the AMEX is based on the Company's failure to meet several of the Exchange's conditions for continued listing.

Presently, the Company continues to be noncompliant with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the Company Guide, all of which relate to the Company's insufficient stockholder's equity as previously reported in the Company's filings with the SEC. The AMEX also cites deficiencies regarding the Company's ongoing losses and low share price as additional reasons for the staff's determination. The Company is currently evaluating its options in dealing with the AMEX and will provide updates as they become available. It is management's view that PreMD's delisting on the AMEX does not affect its current listing on the Toronto Stock Exchange (the "TSX").

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a skin cholesterol test designed for use in the life insurance industry. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
2. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
3. QMed, Inc. Receives NASDAQ Delisting Letter
4. Vion Pharmaceuticals to Appeal Nasdaq Delisting
5. WorldHeart Notified of TSX Delisting Review
6. WorldHeart Announces Possible Delisting Action by NASDAQ
7. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
8. AMICAS Transforms Critical Results Notification with RadStream
9. Merge Technologies Receives Expected Additional NASDAQ Notification
10. Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price
11. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America (BPC), ... reputable physician in their area, announces the launch of a new and proprietary customer ... are looking for reputable physicians to help them with back or neck pain and ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology: